A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone Across All Treatment Lines in Patients with MSI-high or dMMR mCRC By Ogkologos - February 5, 2025 715 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 8HW study Source RELATED ARTICLESMORE FROM AUTHOR Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer Efficacy of Pembrolizumab and Olaparib Combination Observed in a Subset of Patients with HRD Metastatic Pancreatic Cancer MOST POPULAR With Two FDA Approvals, Prostate Cancer Treatment Enters the PARP Era June 11, 2020 Talazoparib Beyond BRCA Prospective Study Identifies the Sensitivity of gPALB2-Associated Breast... October 25, 2022 Cancer in My Community: Developing Pediatric Palliative and Supportive Care in... January 16, 2024 Hospital Lockdown Prevents Breast Cancer Patient from Receiving Treatment for 3... May 17, 2021 Load more HOT NEWS Pyrotinib in HER2-mutated Advanced NSCLC Previously Treated with Chemotherapy Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance... As Winter Storms Plague Southern States, GreaterGood Is Helping Where It’s... Opinion: ‘Let’s not be short-sighted – the UK’s medical research charities...
